Gemcitabine and Carboplatin in Inoperable, Loco-Regionally Advanced and Metastatic Gallbladder Cancer- A Study from Northern Indian Cancer Institute

V. Talwar, S. Raina, Varun Goel, D. Doval
{"title":"Gemcitabine and Carboplatin in Inoperable, Loco-Regionally Advanced and Metastatic Gallbladder Cancer- A Study from Northern Indian Cancer Institute","authors":"V. Talwar, S. Raina, Varun Goel, D. Doval","doi":"10.9734/bjmmr/2017/30843","DOIUrl":null,"url":null,"abstract":"Aims: The primary objective of this study was to determine the response rates of the gemcitabine and carboplatin combination chemotherapy in treatment naïve patients with inoperable gall bladder cancer. The secondary objectives were to evaluate the toxicity, progression free survival (PFS), and overall survival (OS). Methodology: Treatment naïve patients with histologically proven inoperable gall bladder cancer treated with gemcitabine and carboplatin chemotherapy between February 2011 and December 2014 were included in this study. The dose of gemcitabine was 1 gm/m on day 1 and 8, and carboplatin [target AUC (area under the concentration versus time curve in mg/ml) of 5] on day 1, in a 21 day cycle. CT scan was used for response assessment. Original Research Article Talwar et al.; BJMMR, 19(12): 1-7, 2017; Article no.BJMMR.30843 2 Results: There were 32 men and 92 women with a median age of 59 years (range 26-75 years). Of the 124 patients, 9 (7.3%) patients achieved a complete response and 54 (43.5%) patients achieved a partial response for an overall response rate of 50.8%. The median PFS was 4.6 months [95% confidence interval (CI) 4–5.5 months], with 1-year survival rate of 20.2%. Common toxicity criteria (CTC) grade 3 anaemia was seen in 6 (4.8%) patients. Grade 3 and 4 neutropenia was observed in 11 (8.9%) and 4 (3.2%) patients respectively, whereas 9 (7.3%) patients experienced Grade 3 thrombocytopenia. Conclusion: The combination of gemcitabine and carboplatin is active in advanced gall bladder carcinoma with mild toxicity.","PeriodicalId":9249,"journal":{"name":"British journal of medicine and medical research","volume":"11 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of medicine and medical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/bjmmr/2017/30843","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Aims: The primary objective of this study was to determine the response rates of the gemcitabine and carboplatin combination chemotherapy in treatment naïve patients with inoperable gall bladder cancer. The secondary objectives were to evaluate the toxicity, progression free survival (PFS), and overall survival (OS). Methodology: Treatment naïve patients with histologically proven inoperable gall bladder cancer treated with gemcitabine and carboplatin chemotherapy between February 2011 and December 2014 were included in this study. The dose of gemcitabine was 1 gm/m on day 1 and 8, and carboplatin [target AUC (area under the concentration versus time curve in mg/ml) of 5] on day 1, in a 21 day cycle. CT scan was used for response assessment. Original Research Article Talwar et al.; BJMMR, 19(12): 1-7, 2017; Article no.BJMMR.30843 2 Results: There were 32 men and 92 women with a median age of 59 years (range 26-75 years). Of the 124 patients, 9 (7.3%) patients achieved a complete response and 54 (43.5%) patients achieved a partial response for an overall response rate of 50.8%. The median PFS was 4.6 months [95% confidence interval (CI) 4–5.5 months], with 1-year survival rate of 20.2%. Common toxicity criteria (CTC) grade 3 anaemia was seen in 6 (4.8%) patients. Grade 3 and 4 neutropenia was observed in 11 (8.9%) and 4 (3.2%) patients respectively, whereas 9 (7.3%) patients experienced Grade 3 thrombocytopenia. Conclusion: The combination of gemcitabine and carboplatin is active in advanced gall bladder carcinoma with mild toxicity.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
吉西他滨和卡铂治疗不能手术的局部-区域晚期和转移性胆囊癌-北印度癌症研究所的一项研究
目的:本研究的主要目的是确定吉西他滨和卡铂联合化疗治疗naïve不能手术的胆囊癌患者的反应率。次要目标是评估毒性、无进展生存期(PFS)和总生存期(OS)。方法:治疗naïve纳入2011年2月至2014年12月间经组织学证实不能手术的胆囊癌患者,同时接受吉西他滨和卡铂化疗。吉西他滨的剂量在第1天和第8天为1 gm/m,卡铂[目标AUC(浓度-时间曲线下面积,mg/ml)为5]在第1天,21天为一个周期。CT扫描用于疗效评估。Talwar等;地球物理学报,19(12):1-7,2017;文章no.BJMMR。30843 2结果:男性32例,女性92例,中位年龄59岁(26 ~ 75岁)。124例患者中,9例(7.3%)患者达到完全缓解,54例(43.5%)患者达到部分缓解,总缓解率为50.8%。中位PFS为4.6个月[95%可信区间(CI) 4-5.5个月],1年生存率为20.2%。6例(4.8%)患者出现常见毒性标准(CTC) 3级贫血。3级和4级中性粒细胞减少患者分别为11例(8.9%)和4例(3.2%),而3级血小板减少患者为9例(7.3%)。结论:吉西他滨联合卡铂治疗晚期胆囊癌疗效显著,毒性轻。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pattern and Trends of Respiratory Disease Admissions at the Emergency Paediatrics Unit of Jos University Teaching Hospital – A Four Year Review Acquisition of Competence in Clinical Practical Procedures: A Model of the University of Zambia Medical School nternal Medicine as a Career Choice among Rotatory Interns in a Developing Country- A Multi Centre Study Appreciating the Essence of Post Natal Care Services from Mothers’ Perspective in Kiambu, Kenya Phenylthiocarbamide Taste Perception among HIV- Infected Patients on Highly Active Antiretroviral Therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1